سعر ازاثيوبرين ميلان 50 مجم 100 قرص 2026

Azathioprine 50 mg film-coated scored tablets, a purine antimetabolite immunosuppressant, listed in Egypt under Mylan s.a.s (manufactured by Delpharm Lille, France); pack of 100 tablets.

• Organ transplantation (prevention of graft rejection)Population: Adults and childrenBase de données publique des médicaments (ANSM, France)
• Inflammatory bowel disease (Crohn's disease, ulcerative colitis)Population: Adults and childrenBase de données publique des médicaments (ANSM, France)
• Autoimmune diseases: rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis/polymyositis, autoimmune hepatitis, polyarteritis nodosa, pemphigus, autoimmune haemolytic anaemia, chronic refractory idiopathic thrombocytopenic purpuraPopulation: Adults and childrenBase de données publique des médicaments (ANSM, France)

• Very common: infections in transplant patients on combined immunosuppression, bone marrow depression, leukopenia. Common: thrombocytopenia, nausea. Uncommon: anaemia, hypersensitivity, pancreatitis, cholestasis, abnormal liver tests. Rare: agranulocytosis, pancytopenia, aplastic anaemia, neoplasms, life-threatening liver injury, alopecia. Very rare: Stevens-Johnson syndrome/TEN, reversible pneumonitis, PML. Not known: hepatosplenic T-cell lymphoma, pellagra, PRES, sialoadenitis, photosensitivity.International label, equivalent formulation · electronic medicines compendium (eMC)

• Hypersensitivity to azathioprine or excipients; hypersensitivity to 6-mercaptopurine should alert to probable hypersensitivity to azathioprine.International label, same product · Base de données publique des médicaments (ANSM, France)
• Hypersensitivity to azathioprine or to any excipient; hypersensitivity to 6-mercaptopurine should alert to probable hypersensitivity to azathioprine.International label, equivalent formulation · electronic medicines compendium (eMC)
• Hypersensitivity to azathioprine; rheumatoid arthritis patients who are pregnant; rheumatoid arthritis patients previously treated with alkylating agents (e.g. cyclophosphamide, chlorambucil, melphalan) because of a prohibitive risk of malignancy.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Bone marrow depression: prescribe only if toxicity can be monitored; complete blood counts incl. platelets weekly during the first 8 weeks, then monthly or at least every 3 months; interrupt at the first abnormal fall; patients must report infection, unexpected bruising or bleeding.International label, equivalent formulation · electronic medicines compendium (eMC)
• TPMT deficiency and NUDT15 variants increase the risk of severe toxicity at conventional doses and generally need dose reduction; genotypic/phenotypic testing is available but does not identify all at-risk patients, so close blood count monitoring remains necessary.International label, equivalent formulation · electronic medicines compendium (eMC)
• Hepatotoxicity: monitor liver function routinely; non-cirrhotic portal hypertension/portosinusoidal vascular disease reported; patients should report symptoms of liver injury.International label, equivalent formulation · electronic medicines compendium (eMC)

• Allopurinol, oxipurinol, thiopurinolXanthine oxidase inhibition reduces 6-MP inactivation; give only 25% of the usual azathioprine dose; fatal cases reported with allopurinol.electronic medicines compendium (eMC)
• Febuxostat and other xanthine oxidase inhibitorsMay prolong azathioprine activity and enhance marrow suppression; co-administration not recommended.electronic medicines compendium (eMC)
• RibavirinReduces active 6-thioguanine nucleotides; severe myelosuppression reported; co-administration not advised.electronic medicines compendium (eMC)

• Effective contraception is required during treatment and for 6 months after stopping in women, and for 3 months after stopping in men.International label, same product · Base de données publique des médicaments (ANSM, France)
• Substantial transplacental and transamniotic transfer occurs; do not give to patients who are pregnant or likely to become pregnant without careful risk-benefit assessment; adequate contraception is advised when either partner is receiving azathioprine; evidence of teratogenicity in humans is equivocal.International label, equivalent formulation · electronic medicines compendium (eMC)
• Breastfeeding should be avoided unless the expected benefit outweighs the risk.International label, same product · Base de données publique des médicaments (ANSM, France)

• Azathioprine: Prodrug rapidly converted in vivo to 6-mercaptopurine, which is metabolised intracellularly to purine thioanalogues (mainly thioinosinic acid) that interfere with purine synthesis; 6-MP is inactivated by xanthine oxidase (inhibited by allopurinol) and TPMT (UK SmPC 5.1).